LifeMap Sciences, a Subsidiary of BioTime, Inc., Launches LifeMap Discovery™: A Database of Human Cellular Life for the Field

  LifeMap Sciences, a Subsidiary of BioTime, Inc., Launches LifeMap
  Discovery™: A Database of Human Cellular Life for the Field of Regenerative

Business Wire

ALAMEDA, Calif. -- November 27, 2012

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX),
announced today the launch of LifeMap Discovery™ (, a
state-of-the-art roadmap of embryonic development and stem cell biology. The
platform integrates embryonic development and stem cell biology with
molecular, cellular, anatomical, and disease-related information, and provides
data-mining capabilities and bioinformatics applications. LifeMap Discovery™
is a unique and powerful tool for research and discovery in multiple
disciplines, including stem cell biology, developmental biology, disease
mechanisms and etiology, and drug and therapeutic discovery and development.
This new and innovative database is a central element in LifeMap’s discovery
platform for biomedical and stem cell research, which also includes
GeneCards^®, the leading human gene database, and MalaCards, the human disease

The launch of LifeMap Discovery™ represents a key milestone for LifeMap
Sciences. The platform is a central element in the generation of near-term
revenues through paid subscriptions, and is expected to drive traffic to the
recently launched LifeMap BioReagents™ marketing portal, as well as aid in the
company’s therapeutic discovery activities.

Near-term subscription revenues from pharmaceutical and biotechnology

Like GeneCards^® and MalaCards, LifeMap Sciences is making certain aspects of
LifeMap Discovery™ free for use to stem cell researchers at academic
non-profit organizations. Other institutions, including pharmaceuticals and
biotechnology companies, are offered access through paid subscriptions to the

Near-term revenues via research reagent sales through the LifeMap BioReagents™

The LifeMap integrated database suite is expected to drive traffic to LifeMap
Sciences’ LifeMap BioReagents™ portal, providing hundreds of thousands of
biomedical researchers who access these databases a means of identifying
research reagents that can enhance their research and discovery efforts. These
databases currently feature targeted links to the various BioTime PureStem™
human progenitor cell lines, PureStem™ packages, and clinical- and
research-grade human embryonic stem cell lines. Starting in early 2013,
additional links will be provided to other research products that are
complementary to the BioTime stem cell products, which will be available from
LifeMap BioReagents™. With access to the databases, researchers can become
familiar with, and purchase, products that relate directly to the types of
genes, cells, or diseases that they are investigating.

Therapeutic discovery efforts

In addition to the generation of near-term revenues from subscriptions and
sales of research products, LifeMap Sciences’ scientific team is utilizing
LifeMap Discovery™ to research and identify PureStem™ human progenitor cell
lines (also known as ACTCellerate™ lines) likely to be useful in the research
and development of cell-based regenerative medicine therapies for a wide range
of diseases. Once identified, selected cell lines will be marketed by LifeMap
Sciences for research purposes via the recently launched LifeMap BioReagents™
portal, and these unique lines may eventually be advanced to therapeutic
development by BioTime and/or LifeMap Sciences.

“The launch of the LifeMap Discovery™ database is a significant milestone in
the emerging field of regenerative medicine and a tribute to the tireless
efforts of the scientific and development teams at LifeMap Sciences,” said
Michael D. West, PhD, President and Chief Executive Officer of BioTime. “The
power of embryonic stem cells to transform into all of the cell types in the
human body is at once both their greatest opportunity and challenge. Many of
the degenerative diseases afflicting our aging population are caused by a lack
of functional cells capable of regenerating particular tissues in the body.
Until recently, the field has suffered from the lack of a “roadmap” directing
scientists through the many hundreds of branch points in the stems of the tree
of human cellular life. Together with GeneCards^®  and MalaCards, LifeMap
Discovery™ provides the beginning of an online directory that may help us see
the day when lifesaving stem cell-based therapies reach the people so
desperately in need of them.”

A video describing some of the features of LifeMap Discovery™ is available for
online viewing at

"Over the past 18 months, our multidisciplinary team has put forth tremendous
effort to design and build an integrated, cutting-edge database of embryonic
development, stem cell research, and regenerative medicine, tying together
molecular, cellular, anatomical, and disease-related information into one
user-friendly database,” said David Warshawsky, PhD, LifeMap Sciences’ Chief
Executive Officer. “We expect LifeMap Discovery™ to have a profound effect on
the ability of researchers in academia and industry worldwide to advance
research in the stem cell field, and in other biomedical fields, and to
advance the ability to develop novel diagnostic and therapeutic products and

About LifeMap Sciences, Inc.

LifeMap Sciences’ ( core technology and business is based on
its integrated database suite, the discovery platform for biomedical and stem
cell research. This platform includes GeneCards^®, the leading human gene
database; LifeMap Discovery™, the database of embryonic development, stem cell
research, and regenerative medicine; and MalaCards, the human disease
database. LifeMap Sciences also markets PanDaTox, an innovative, recently
developed, searchable database that can aid in the discovery of new
antibiotics and biotechnologically beneficial products.

In addition to database offerings, BioTime plans to make LifeMap Sciences
BioTime’s principal marketing subsidiary for research products, including
PureStem™ human progenitor cell lines, GMP human embryonic stem (hES) cell
lines, growth media for progenitor cell lines, and cell differentiation kits,
for non-therapeutic uses, via its LifeMap BioReagents™ portal. LifeMap
Sciences will utilize its databases as part of its online marketing strategy
to reach life sciences researchers at biotech and pharmaceutical companies and
at academic institutions and research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMap’s scientists
utilize LifeMap’s proprietary platform, including LifeMap Discovery, its stem
cell database along with the GeneCards^® and MalaCards integrated database
suite, to aid in the development of BioTime’s proprietary PureStem™ human
progenitor cell lines into products for the treatment of human diseases,
especially degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform will be used to select the
progenitor cell lines that are most likely to be useful in developing
cell-based regenerative medicine therapies for a wide range of diseases.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, and is developing
an integrated database suite to complement GeneCards^® that will also include
the LifeMap™ database of embryonic development, stem cell research and
regenerative medicine, and MalaCards, the human disease database. LifeMap will
also market BioTime research products. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:


BioTime, Inc.
Peter Garcia, 510-521-3390 ext. 367
Chief Financial Officer
Judith Segall, 510-521-3390 ext. 301
LifeMap Sciences, Inc.
Kenneth Elsner, 781-826-7719
Press spacebar to pause and continue. Press esc to stop.